A complete go-to-market kit built for Citizen Health Life Sciences — landing pages, display ads, decks, one-pagers, ebook covers, and nurture sequences across four target angles.
Citizen Health Life Sciences sells the same platform — regulatory-grade real-world data + recontactable patient registries — to four very different audiences. We built the kit for each.
Gene therapy + rare disease pipeline acceleration with FDA-grade natural history data and recontactable cohorts.
→Decade-long longitudinal RWE for SMA, ALS, Friedreich's, Huntington's — built for label expansions.
→UCSF, St. Jude, CHOP, Boston Children's, Emory — investigator-led research without the registry build.
→Turnkey patient registries for rare-disease foundations. Owned by your community, powered by Citizen Health.
→We pitched Novartis Rare Disease teams the angle that compresses pre-IND, pivotal, and post-market evidence onto one longitudinal cohort. Recontactable, FDA-accepted, ready before they file.
From SMA Spinraza to Friedreich's Skyclarys to Alzheimer's Leqembi — every Biogen label depends on RWE that only a recontactable patient registry can produce. We pitched Biogen Neurology the cohort infrastructure.
UCSF, St. Jude, CHOP, Boston Children's, Emory and Mass General PIs need recontactable cohorts in 6 weeks, not 18 months. Citizen Health data already powered a Brain journal paper on STXBP1 — yours next.
80+ rare-disease foundations already run their patient community on Citizen Health. We pitched the next batch — NORD, Global Genes, EveryLife, and the founders building the next CACNA1A or Cohen Syndrome Foundation.
